J R Smith

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. doi request reprint Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment
    J R Smith
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Int J Clin Pract 63:596-605. 2009
  2. doi request reprint The use of antiviral agents for the management of severe influenza
    James R Smith
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Crit Care Med 38:e43-51. 2010
  3. pmc Oseltamivir in human avian influenza infection
    James R Smith
    F Hoffmann La Roche Ltd, Basel, Switzerland
    J Antimicrob Chemother 65:ii25-ii33. 2010
  4. doi request reprint Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience
    James R Smith
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, PBMT Bldg 74 3O Z1 06, CH 4070, Basel, Switzerland
    Adv Ther 28:927-59. 2011
  5. ncbi request reprint Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study
    M Brewster
    PDMP Clinical Science, Roche Products Ltd, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW, UK
    Vaccine 24:6660-3. 2006

Detail Information

Publications5

  1. doi request reprint Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment
    J R Smith
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Int J Clin Pract 63:596-605. 2009
    ..In this study, the incidence of neuropsychiatric events in influenza patients dispensed oseltamivir or no antiviral was assessed using a large US medical claims database...
  2. doi request reprint The use of antiviral agents for the management of severe influenza
    James R Smith
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Crit Care Med 38:e43-51. 2010
    ..Very little resistance to oseltamivir has been found to date...
  3. pmc Oseltamivir in human avian influenza infection
    James R Smith
    F Hoffmann La Roche Ltd, Basel, Switzerland
    J Antimicrob Chemother 65:ii25-ii33. 2010
    ..Roche is also funding the Avian Influenza Registry, an online database that aims to collect information from clinicians worldwide on the course of avian influenza in humans...
  4. doi request reprint Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience
    James R Smith
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, PBMT Bldg 74 3O Z1 06, CH 4070, Basel, Switzerland
    Adv Ther 28:927-59. 2011
    ..Finally, the article considers the pharmacoeconomics of oseltamivir in comparison with vaccination and usual care regimens, and as a component of pandemic influenza mitigation strategies...
  5. ncbi request reprint Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study
    M Brewster
    PDMP Clinical Science, Roche Products Ltd, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW, UK
    Vaccine 24:6660-3. 2006
    ..93-1.08]). Thus, the two formulations were bioequivalent for oseltamivir carboxylate. For pandemic stockpiling of Tamiflu, governments can therefore choose between the capsule formulation alone, the API alone, or quantities of both...